The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors

被引：0
|
作者：
El-Khoueiry, Anthony B.
Song, Paul Y.
Rubel, Jennifer
Pourang, Dorna Y.
Raab, Christa
Hintzen, Gabriele
Emig, Michael
Nava-Parada, Pilar
机构：
[1] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[2] NKGen BioTech Inc, Santa Ana, CA USA
[3] Affimed Inc, New York, NY USA
[4] Affimed GmbH, Heidelberg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2675
引用
收藏
页数：1
相关论文
共 36 条
  • [31] DEVELOPING PLACENTAL CD34+-DERIVED NATURAL KILLER CELLS WITH HIGH AFFINITY AND CLEAVAGE RESISTANT CD16 (CYNK-101) IN COMBINATION WITH AVELUMAB FOR ENHANCED THERAPY AGAINST PD-L1+ SOLID TUMORS
    Raitman, Irene
    Foley, Gavin
    He, Eric
    Rana, Hemlata
    Ghimire, Niranjan
    Guo, Xuan
    Hariri, Robert
    Kang, Lin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A285 - A285
  • [32] A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR 3 CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
    Weickhardt, A. J.
    Frentzas, S.
    Lemech, C.
    Srimani, J.
    Yin, J.
    Trepicchio, W. L.
    Gorgun, C.
    Kichenadasse, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S492 - S492
  • [33] A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors
    Schwarze, J. K.
    Awada, G.
    Van Riet, I.
    Neyns, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.
    Schwarze, Julia Katharina
    Awada, Gil
    Cras, Louise
    Forsyth, Ramses
    Van Riet, Ivan
    Neyns, Bart
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] AFNT-211: A phase1 study of autologous CD4+and CD8+T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
    Mitchell, Shaunica
    Khan, Binaish
    Payumo, Francis
    Chiorean, E. Gabriela
    Gahvari, Zhubin
    Hecht, J. Randolph
    Hurwitz, Michael
    Leidner, Rom
    Lenz, Heinz-Josef
    Pelster, Meredith
    Punekar, Salman
    Schoenfeld, Adam
    Zhao, Dan
    Vallaster, Markus
    Nagorsen, Dirk
    CANCER RESEARCH, 2024, 84 (07)
  • [36] AFNT-211: A phase 1 study of autologous CD4+and CD8+T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
    Mitchell, Shaunica
    Khan, Binaish
    Payumo, Francis
    Chiorean, E. Gabriela
    Gahvari, Zhubin
    Hecht, J. Randolph
    Hurwitz, Michael E.
    Leidner, Rom
    Lenz, Heinz-Josef
    Pelster, Meredith
    Punekar, Salman Rafi
    Schoenfeld, Adam Jacob
    Zhao, Dan
    Vallaster, Markus P.
    Nagorsen, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
1234